Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Immatics N.V.: Considering More Engineered T Cells For Cancer

IGM Biosciences Stock: Bad News With No Turnaround In Sight

Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Nuvectis Pharma: Still Flat, Although There May Be A Ground Floor Here

Enliven Therapeutics: Still Too Early To Pay This Much

Cabaletta Bio: Finding Optimism In Dire Straits

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Verastem: NDA Acceptance Puts Key Goals In Sight

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else?

TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut

Korro Bio: Still Too Long To Go... Just Keep Watching For Now (Rating Upgrade)

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Mesoblast Finally Gets Its Approval In GVHD: Where Now?